




The relative strengths and weaknesses of Aclaris Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aclaris Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 107% points. The greatest weakness of Aclaris Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 312%, being 99% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	128,856
Cost of Goods Sold	3,423
Intangible Assets	269
Liabilities, Current	30,952
Liabilities, Non-Current	3,074
Other Assets	66,660
Other Compr. Net Income	791
Other Expenses	-5,980
Other Liabilities	6,200
Other Net Income	8,509
Other Revenues	31,249
Property and Equipment	1,620
Research and Development	98,384
Selling, General and Administrative Expense	32,412

Output Variable	Value in 1000 USD
Assets	197,405
Liabilities	40,226
Expenses	128,239
Revenues	31,249
Stockholders Equity	157,179
Net Income	-88,481
Comprehensive Net Income	-88,086
BaseVar	203,210
ECR before LimitedLiability	214%
Economic Capital Ratio	312%